What did @cristina.noh actually say?
The creator described her personal transition from compounded tirzepatide (17 mg weekly) to retatrutide, using cagrilinitide as a bridge to manage hunger during the switch. She said she took a two-week break from tirzepatide, then started retatrutide at 1 mg and titrated up by 1 mg weekly, landing at 6 mg as her maintenance dose. She was transparent that she works with a medical professional throughout this process and explicitly told viewers not to follow her protocol without their own provider's guidance. She also mentioned adding 50 mg weekly of cagrilinitide for appetite control during the taper.
To her credit, she repeated the medical supervision disclaimer multiple times, did not claim these peptides cure or treat specific diseases by name, and actively pointed viewers toward a licensed practitioner rather than a direct-to-consumer storefront. That's more responsible than most peptide content on TikTok. But the specific numbers she shared, a 17 mg tirzepatide dose, a 1 mg retatrutide starting point, 50 mg cagrilinitide weekly, are detailed enough to function as informal dosing guidance whether she intends them to or not.
Does the science back this up?
Partially, but there are significant gaps. Retatrutide has real clinical data behind it, which is more than you can say for most peptides discussed in this space. Tirzepatide also has solid evidence. Cagrilinitide is where things get murkier for this specific use case.
Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors. A 2023 Phase 2 trial published in the New England Journal of Medicine (Jastreboff et al., 2023) showed participants on 12 mg weekly lost an average of 17.5% of body weight at 24 weeks, which is genuinely impressive data. However, that trial used specific titration schedules designed to minimize GI side effects, not the informal 1 mg weekly ramp described in the video.
Cagrilinitide is a long-acting amylin analog. A 2021 study in The Lancet (Lau et al., 2021) found cagrilinitide plus semaglutide produced synergistic weight loss versus either drug alone. Using it as a bridge agent during a GLP-1 class switch is pharmacologically plausible, but there are no published studies examining this specific combination or transition strategy. The 50 mg dose she mentions is within the range studied in trials, but applying trial doses to individual off-label use is not the same thing.
What did they get wrong (or right)?
She got the transparency piece mostly right. Pointing viewers to a practitioner who requires a consultation before dispensing is the correct framework, and she deserves credit for that.
What she got wrong, or at least incomplete, is the framing around cagrilinitide as a hunger suppression tool during a GLP-1 transition. She says adding 50 mg of cagrilinitide weekly helped her taper off tirzepatide. That is a plausible mechanism, amylin signaling does contribute to satiety, but presenting it as a clean, obvious solution obscures the fact that combining two weight-loss compounds during a washout period from a third carries real interaction risk that has not been studied in this configuration.
The 17 mg tirzepatide dose also deserves a note. The FDA-approved maximum dose for Zepbound and Mounjaro is 15 mg weekly. Compounded tirzepatide at 17 mg is above that ceiling. She is transparent that it came from a compounding pharmacy, but the video does not explain that this exceeds the approved dosing range for the branded product, which is a meaningful omission for a 20,000-person audience.
What should you actually know?
Retatrutide is not FDA-approved as of mid-2025. It is in clinical trials. Any retatrutide you obtain today is compounded, which means quality, purity, and dosing accuracy vary by pharmacy. That is not a theoretical concern. A 2024 FDA safety communication flagged multiple adverse event reports tied to compounded GLP-1 and GLP-1 adjacent peptides, including dosing errors due to concentration variability.
Transitioning between GLP-1 class drugs is not as simple as a two-week break and a slow titration. Weight regain risk during any washout period is real. Jastreboff et al. (2022, NEJM) showed that stopping semaglutide led to substantial weight regain within a year, suggesting discontinuation periods carry their own risks. A supervised transition with labs and regular check-ins is not optional, it is the minimum standard of care.
Cagrilinitide is also not available through most U.S. telehealth platforms in a verified compounded form. If someone is sourcing it without a clear pharmaceutical trail, the identity and purity of what they are injecting is genuinely unknown.